Strive response

email forwarded by a friend

We're getting sued by Eli Lilly. When we decided to continue compounding Tirzepatide for clinically significant reasons, we did that knowing that a response from Eli Lilly would happen eventually. As Strive has grown in size and impact, it’s also grown the amount of attention we receive. We consider that a blessing and an opportunity for us to create more awareness about the world of personalized healthcare and the role that compounding pharmacies play. As we strive to disrupt an industry that’s lost sight of its purpose by bringing it back to the roots—sustainable health and personalized care, obstacles like this come with the territory. This situation is creating a lot of press and questions, to which we’re replying with this official statement: “This isn’t just an attack on Strive Pharmacy, this is an attack on personalized medicine, patient access, patient choice, and healthcare provider discretion. This is a classic example of Big Pharma overstepping legitimate regulations and prioritizing their own interests over patients’ and the general public is catching on. If Strive Pharmacy is the only one holding the line, so be it. Our patients and providers deserve our effort. Strive will vigorously defend our position and we look forward to being vindicated in the courts.” We are fighting for more than ourselves. Strive is all about the people. We exist to enable fuller, healthier lives for people. We proudly represent the “personal side of healthcare.” As far as the compounding of Tirzepatide goes, we’re business as usual:

The Strive Team